AstraZeneca Canada Inc. has introduced a support program designed to take cost out of the equation in the patient’s choice between Nexium tablets and a generic esomeprazole product.
It was the recommendations of a six-member advisory panel on health system sustainability that probably got the most mainstream journalism coverage at this year’s CMA meeting.